Acne 

Actinic Keratosis 

Aesthetics

Biologic Treatments for Moderate to Severe Atopic Dermatitis 

Atopic Dermatitis 

COVID-19

Drug Watch

Dry Cracked Skin

Hidradentitis Suppurativa

Impetigo

Inflamed Skin

Melasma

NP and PA

Pediatric Dermatology

Pigmentary Disorders 

Practice Management 

Precision Medicine and Biologics

Emerging Therapies Plaque Psoriasis

Treatments for Plaque Psoriasis 

Psoriasis 

Psoriatic Arthritis 

Rare Disease

Rosacea 

Skin Cancer (Nonmelanoma)

Skin Cancer

Surgery

Vitiligo

Wound Care

News

Media

2 Minute Drill

Around the Practice

Between The Lines

Case Based Peer Perspective

DermView

Editorial Board News

Expert Interviews

Expert Perspectives

Frontline Forum

Inside the Clinic

Medical World News

Patient Perspectives

Podcasts

Readout360

Recognize and Refer

Viewpoints

Webinars

Conferences

Conference Coverage

Conference Listing

Publication

Dermatology Times

CME/CE

Resources

DermIQ

Image IQ

Interactive Tools

Job Board

Polls

Editorial Advisory Board

Partnerships

Subscribe

Print Subscription

eNewsletter

 and joined the MJH Life Sciences team in June 2022. She attended Otterbein University in Westerville, Ohio, and earned a Bachelor of Arts degree in literary studies with minors in creative writing and film studies. Prior to health care news, Kaitlyn worked in industrial marketing. She enjoys cooking, reading, and tending to her house plants. 

Articles

This week’s collection of the latest dermatologic studies covers chronic pruritus of unknown origin, vaccinating dermatology providers for HPV, body dysmorphic disorder among Lebanese women, and a case report of a pleomorphic dermal sarcoma with metastasis to the lung. 

Journal Digest: September 26 

and joined the MJH Life Sciences team in February 2023. She attended Kent State University and earned a Bachelor of Science degree in journalism with minors in public relations and creative writing. She enjoys making and listening to music, reading, and spending time with her cats, Astrid and Marceline.

Sachin Shridharani, MD, discusses the results of a recent Allergan Aesthetics study exploring the efficacy of onabotulinumtoxinA in treating platysma prominence.

Phase 3 Trial Data Highlights Efficacy of OnabotulinutoxinA in Platysma Prominence

Ruth Ann Vleugels, MD, and Christopher Bunick, MD, agreed that the long-term safety data for JAK inhibitors makes them preferable to systemic steroids.

Analyzing the Safety of JAK Inhibitors in Atopic Dermatitis Treatment

Abeona Therapeutics is seeking Priority Review and approval of the therapy for patients with recessive dystrophic epidermolysis bullosa.

Abeona Submits Biologics License Application to FDA for EB-101

Advertise

Contact Us

Do Not Sell My Information

Terms and Conditions

Privacy Policy

Dermatology Times and Multimedia Medical, LLC

Twitter

Facebook

Linkedin

Topics

Acne

Anti-Aging

BPDCN

Hair & Scalp

Rosacea

Skin Cancer (Melanoma)

Skin Cancer (Non-Melanoma)

1rem

Authors

Many dermatologists are approached by parties interested in acquiring a practice.  Knowing ahead of time what questions you should ask-and how to answer their questions-can turn a simple inquiry by them into a wealth of information for you.

What should dermatologists do when a merger beckons?

Patrick Krause

Articles